Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07‐03

Escherich, Gabriele; Zimmermann, Martin; Janka‐Schaub, Gritta

doi:10.1002/pbc.24273

Cited by 34 publications

(32 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study comprised 574 children with newly diagnosed BCP-ALL enrolled in consecutive Dutch Childhood Oncology Group trials (DCOG ALL-8, ALL-9 and ALL-10) [5, 22] and German Cooperative ALL trials (COALL 06-97 and 07-03) [23–24]. These patient cohorts were described and analyzed together previously [3, 5].…”

Section: Methodsmentioning

confidence: 99%

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia

et al. 2016

Self Cite

View full text Add to dashboard Cite

Approximately 15% of pediatric B cell precursor acute lymphoblastic leukemia (BCP-ALL) is characterized by gene expression similar to that of BCR-ABL1-positive disease and unfavorable prognosis. This BCR-ABL1-like subtype shows a high frequency of B-cell development gene aberrations and tyrosine kinase-activating lesions. To evaluate the clinical significance of tyrosine kinase gene fusions in children with BCP-ALL, we studied the frequency of recently identified tyrosine kinase fusions, associated genetic features, and prognosis in a representative Dutch/German cohort. We identified 14 tyrosine kinase fusions among 77 BCR-ABL1-like cases (18%) and none among 76 non-BCR-ABL1-like B-other cases. Novel exon fusions were identified for RCSD1-ABL2 and TERF2-JAK2. JAK2 mutation was mutually exclusive with tyrosine kinase fusions and only occurred in cases with high CRLF2 expression. The non/late response rate and levels of minimal residual disease in the fusion-positive BCR-ABL1-like group were higher than in the non-BCR-ABL1-like B-others (p<0.01), and also higher, albeit not statistically significant, compared with the fusion-negative BCR-ABL1-like group. The 8-year cumulative incidence of relapse in the fusion-positive BCR-ABL1-like group (35%) was comparable with that in the fusion-negative BCR-ABL1-like group (35%), and worse than in the non-BCR-ABL1-like B-other group (17%, p=0.07). IKZF1 deletions, predominantly other than the dominant-negative isoform and full deletion, co-occurred with tyrosine kinase fusions. This study shows that tyrosine kinase fusion-positive cases are a high-risk subtype of BCP-ALL, which warrants further studies with specific kinase inhibitors to improve outcome.

show abstract

Section: Methodsmentioning

confidence: 99%

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Both anthracyclines have been shown to have similar efficacy and toxicity in randomized trials. 14 Certain groups spare the addition of anthracyclines to those lower-risk groups in an effort to decrease toxicity. The corticosteroid used is usually prednisone or dexamethasone, with dexamethasone demonstrating improved CNS penetration and decreased risk of relapse, but with increased incidence of toxicities, including avascular necrosis, infection, and reduction in linear growth.…”

Section: Treatment Of Newly Diagnosed Acute Lymphoblastic Leukemiamentioning

confidence: 99%

Treatment of Pediatric Acute Lymphoblastic Leukemia

Cooper

Brown

2015

Pediatric Clinics of North America

278

222

View full text Add to dashboard Cite

“…Doxorubicin (DXR) is a quinone‐containing anthracycline antibiotic that is highly effective to treat hematologic and solid malignancies . Unfortunately, the clinical use of DXR is curtailed by inducing cardiomyopathy and nephropathy .…”

Section: Introductionmentioning

confidence: 99%

Protective effect of a direct renin inhibitor in acute murine model of cardiotoxicity and nephrotoxicity

Rashikh

Pillai

Najmi

2013

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

This study aimed to investigate the possible protective effects of aliskiren against doxorubicin (DXR)-induced cardiorenal injury and to identify the mechanisms involved. Intraperitoneal administration of DXR (15 mg/kg, body weight, as a single dose) caused significant induction in the levels of angiotensin I, caspase-3, lactate dehydrogenase (LDH), lipid peroxidation malondialdehyde (MDA), urea, and creatinine. Concomitant decline in the levels of albumin and total protein in plasma, reduction in reduced glutathione (GSH), and antiperoxidative enzyme superoxide dismutase (SOD) levels followed by ultrastructural alterations in the myocardial and renal tissues were also observed. Oral administration of aliskiren (100 mg/kg, for a period of 14 days) significantly prevented all these DXR-induced adverse effects and maintained the rats near to normal status. However, telmisartan (10 mg/kg) pretreatment has shown slight protection in DXR-induced renal injury as evidenced by broadening of podocyte foot process and narrowing of slit pore diameter. The results of aliskiren were compared with telmisartan which was used as reference in this study. These results suggested that aliskiren has protective effects against acute model of DXR-induced cardiotoxicity and nephrotoxicity, implying that plasma renin activity plays a role in DXR-induced cardio-renal injury.

show abstract

Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07‐03

Abstract: In vivo efficacy of a single dose daunorubicin 30 or 40 mg/m(2) is similar to that of doxorubicin given in a dose of 30 mg/m(2) .

Cited by 34 publications

References 17 publications

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia

Treatment of Pediatric Acute Lymphoblastic Leukemia

Protective effect of a direct renin inhibitor in acute murine model of cardiotoxicity and nephrotoxicity

Contact Info

Product

Resources

About